Biosimilars are changing the way healthcare systems manage the high cost of advanced medicines. These drugs are developed to be very similar to existing biologic treatments, which are often expensive but essential for patients with conditions such as cancer, diabetes, and autoimmune diseases. By offering equally safe and effective alternatives at a lower cost, biosimilars are helping make critical therapies more affordable and accessible.
This article explores what biosimilars are, how they differ from generics, and their significance in modern medicine. It also examines global regulatory pathways, development challenges, market trends, and the prospects of this expanding field.
What Are Biosimilars?
A biosimilar is a biological medicine that is highly similar to an already approved biologic drug. Importantly, an FDA‑approved biosimilar has no clinically meaningful differences in safety, purity, or potency compared to its reference product. In practical terms, patients can expect the same treatment results with a biosimilar as with the original biologic. Biosimilars are made using living cells or organisms (just like their reference biologics) and undergo rigorous comparative studies to ensure they match the reference drug in terms of structure, function, and clinical effect.¹
The introduction of biosimilars offers new therapeutic options, increasing competition, and potentially lowering costs for life‑saving treatments. For example, the World Health Organization notes that biosimilars are often about 60% cheaper than the original biologic products, which can significantly expand patient access to essential medicines, especially for costly conditions like cancer or autoimmune diseases.²
Biosimilars vs. Generics: Key Differences
Biosimilars and generics both aim to provide affordable alternatives to brand‑name drugs, but they are not the same. Generics are small‑molecule medicines made through chemical synthesis and are exact copies of their original drugs. Biosimilars, on the other hand, are large, complex proteins produced in living systems, making it impossible to create an identical copy. Instead, biosimilars must be shown to be highly similar to the reference biologic, with no meaningful differences in safety or effectiveness.
Both are approved through abbreviated regulatory pathways, but the process for biosimilars is more demanding. While generic approval mainly relies on proving chemical equivalence and bioavailability, biosimilar developers must conduct advanced analytical studies and, often, clinical trials to demonstrate similarity. This makes biosimilars more challenging and costly to produce than generics.
Despite these differences, both FDA‑approved generics and biosimilars meet strict safety and quality standards. In the U.S., biosimilars may also receive an “interchangeable” designation, allowing pharmacists to substitute them for the reference biologic without a new prescription, provided additional switching studies confirm safety.
Global Regulatory Pathways for Biosimilars
Around the world, health regulators have created clear frameworks to approve biosimilars, recognizing their role in making advanced therapies more affordable and accessible.
The European Union (EU) was the first to take the lead. In 2003, it set up a legal framework for biosimilars, and by 2006, the European Medicines Agency (EMA) had approved the world’s first biosimilar, a growth hormone called somatropin. Since then, the EMA has built one of the most robust systems for evaluating biosimilarity. By mid‑2025, it had already recommended more than 140 biosimilars for approval across different therapeutic areas. Europe’s experience has shown that biosimilars can be safely introduced into healthcare systems, setting an example for the rest of the world.³
In the United States, the biosimilar approval pathway was created in 2010 through the Biologics Price Competition and Innovation Act (BPCIA). The FDA approved its first biosimila...
(All Rights Reserved)